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Background: Patients with sickle cell disease in the USA have been noted to have lower levels of vitamin
D – measured as 25-hydroxyvitamin D (25(OH)D) – compared to controls. Average serum 25(OH)D levels are
also substantially lower in African Americans than whites, while population distributions of 25(OH)D among
Jamaicans of African descent and West Africans are the same as among USA whites. The purpose of this
study was to examine whether adult patients with sickle cell disease living in tropical regions had reduced
25(OH)D relative to the general population.
Methods: We analyzed serum 25(OH)D in stored samples collected from studies in Jamaica and West Africa
of adult patients with sickle cell disease and adult population controls.
Results: In samples of 20 Jamaicans and 50 West Africans with sickle cell disease mean values of 25(OH)D
were 37% and 39% lower than controls, respectively. Metabolic abnormalities in the absorption and conversion
pathways are possible causes for the consistent relative deficiency of 25(OH)D in sickle cell disease.
Conclusions: Low 25(OH)D levels in tropical Africa where the burden of sickle cell disease is highest, deserve further
investigation, and a randomized trial is warranted to address efficacy of supplementation.
Keywords: Sickle cell disease, Sickle cell anemia, Vitamin D, 25-hydroxyvitamin D, Adult patients, Tropical Africa,
Jamaica, West AfricaBackground
Vitamin D receptors are expressed ubiquitously in hu-
man tissues suggesting that this hormone has numerous
regulatory functions. Other than its role in bone-mineral
metabolism, clear evidence that variation in vitamin D
measured as 25-hydroxyvitamin D (25(OH)D) influences
health outcomes has been difficult to obtain [1]. Several
reports from North America have documented lower 25
(OH)D levels in patients with sickle cell disease (SCD)
compared to age-matched controls [2-6]. A correlation
between low 25(OH)D and severity of the course of SCD
has also been observed and a recent case report de-
scribed dramatic improvement in pain symptoms after
vitamin D supplementation in a SCD patient with severe
osteoporosis and profound vitamin D deficiency [2]. A* Correspondence: btayo@luc.edu
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unless otherwise stated.subsequent pilot randomized trial that enrolled 46 pa-
tients with SCD demonstrated a significant reduction in
days with pain with improved physical-activity-related
quality of life after supplementation with high dose vita-
min D [7]. The authors of these reports suggest that low
25(OH)D may contribute specifically to the almost uni-
versal problem of chronic daily pain observed in SCD,
perhaps by impairing bone health [7].
Serum 25(OH)D levels are strongly influenced by the
amount of ultraviolet radiation that passes through the
outer layer of the skin and reaches vascular tissue. In
turn, the latitude of a person’s residence and the degree
of skin pigmentation determine the amount of radiation
(i.e., ultraviolet B [UVB] to which these tissues are ex-
posed. Dietary sources of vitamin D generally make only
a small contribution to body stores. 25(OH)D levels are
further influenced by genetic variation in receptors and
other components of this biological system [8-11]. It is
generally believed that strong evolutionary selection –d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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accounts for the clinal variation in skin color seen in hu-
man populations in relation to latitude [12-14]. Other
known factors that influence 25(OH)D include age, adi-
posity and some chronic medical conditions (e.g., chronic
kidney disease, use of steroids, etc.).
The underlying basis for the relative deficiency of
25(OH)D among individuals of African descent is un-
known, but could reflect absorption or endogenous meta-
bolic abnormalities. To our knowledge, no reports have
yet examined 25(OH)D levels in SCD patients of African
heritage living near the equator. In this report we con-




West African SCD patients were recruited from the clinics
at the University College Hospital in Ibadan, Nigeria [15].
A random sample of patients were approached and asked
to participate without regard to clinical status. Only pa-
tients in steady state were recruited and included in the
present study. Because clinical exam of SCD patients
at the College Hospital included laboratory analyses,
some data on markers of renal or liver function such as
creatinine, urea, aspartate transaminase, and alanine
transaminase generated at the University College Hospital
Laboratory as part of routine clinical workup were avail-
able on the SCD patients. Population controls were drawn
from a population-based cohort study of energy expend-
iture from Ghana [16]. Nigeria and Ghana are in the same
geographical region in West Africa (Ghana's latitude
and longitude is 8° N and 2° W, and Nigeria's latitude
and longitude is 10° N and 8° E). There were no reported
current uses of vitamin D supplements among the SCD
patients and the population controls at the time of subject
recruitment. Recruitment of SCD patients and controls
took place over multiple years and across both dry and
wet seasons.
For the Jamaican SCD patients, specimens were chosen
from stored plasma from patients being followed at the
Sickle Cell Clinic at the University of the West Indies,
Mona, Kingston, Jamaica. Apart from being at steady
state, no criteria were applied to sample selection. Popula-
tion controls were drawn from a second population-based
cohort study of energy expenditure from Jamaica; this
study included similar numbers of men and women [16].
Both the SCD cohort and the population-based cohort
studies were done across seasons and spanned multiple
years. Because samples for the Jamaican SCD patients
had been drawn and stored for intervals up to 10 years,
we therefore performed assessment of reliability of stored
samples by analyzing duplicate samples from different
follow-up years to assess possible effect of storage onserum 25(OH)D. The correlation between duplicate assays
was 0.8 and the absolute mean difference 9.0 nmol/l;
this is in agreement with reports that stability of serum
25(OH)D is unaffected by multiple freeze-thaw cycles or
long-term storage [17,18].
Anthropometric measurements
Anthropometric measurements in all study samples were
performed and recorded by trained research staff. Informa-
tion on age, height and body weight on all study subjects
in the four samples were obtained by use of standardized
physical exams. Height was measured using a stadiometer
consisting of a steel tape attached to a straight wall and a
wooden headboard. The headboard was positioned with
the subject shoeless, feet and back against the wall, and
head held in the Frankfort horizontal plane and measure-
ment taken to the nearest 0.1 cm. Body weight was mea-
sured to the nearest 0.2 kg on calibrated electronic scales.
Body mass index (BMI) was calculated as weight in kilo-
grams divided by the square of height in meters.
Laboratory assays
All measurements were made at outpatient clinics located
in the communities. Standardized protocols were used for
blood sampling. Specimens were immediately processed
to separate plasma and then frozen. Frozen plasma sam-
ples from both West African and Jamaican study sites
were shipped to and stored in Chicago from where they
were sent to the Department of Laboratory Medicine at
the University of Washington for vitamin D analysis. The
liquid chromatography-tandem mass spectrometric assay
of vitamin D metabolites was performed as described pre-
viously [19,20]. The calibration of the assay was verified
using the National Institute of Standards and Technology
standard reference material (SRM) 972. Interassay vari-
ability was 6.0% at 28.7 nmol/l and 5.6% at 30.7 nmol/l for
25(OH)D2 and 25(OH)D3, respectively.
Statistical analysis
Descriptive characteristics of the cohorts are presented
as means and standard deviations (SD) when continuous
variables were considered, and as frequencies for cat-
egorical variables. A generalized linear regression model
was used to adjust for age, body mass index (BMI), and
sex in the comparison of cases with the control samples.
Statistical significance was set at the value of p < 0.05. All
statistical analyses were performed using SAS 9.3 (SAS
Institute, Cary, NC, USA). This research adhered to guide-
lines for Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) [21].
Ethical considerations for human subjects
The protocols for these studies were reviewed and ap-
proved by the Institutional Review Board at Loyola
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Hospital of the West Indies/University of the West Indies/
Faculty of Medical Sciences Ethics Committee, Mona,
Kingston, Jamaica (ECP 06 2009/2010); the Committee
on Human Research Publication and Ethics of Kwame
Nkrumah University of Science and Technology, Kumasi,
Ghana; and the Joint Ethical Committee of the University of
Ibadan/University College Hospital, Ibadan, Nigeria. Written
informed consent was obtained from all participants.
Results
Descriptive characteristics of subjects in the present
study are presented in Table 1. The number of male sub-
jects is about the same as the number of the female sub-
jects within each of the four study samples. Patients in
the SCD cohorts were young adults, had mean ages sub-
stantially below the controls in both Jamaica (23.7 ± 2.8
vs. 34.3 ± 6.0 years) and West Africa (23.3 ± 4.4 vs. 34.3 ±
6.7 years). Also, the SCD patients were extremely lean,
they were on average 7.2 kg/m2 and 4.7 kg/m2 lighter than
their corresponding Jamaican and West African popula-
tion controls, respectively.
Figure 1 presents a scatter plot of 25(OH)D values in
the four study samples. Despite some overlap, the results
clearly separated into two distinct distributions. There
were a few outlier values among the control study sam-
ples. The mean levels of 25(OH)D were lower in SCD
patients than in controls in either Jamaica (45.4 ± 16.7
vs. 72.2 ± 17.8 nmol/l) or West Africa (46.5 ± 12.8 vs.
75.9 ± 17.2 nmol/l) after covariate adjustment for sex,
age and BMI (Table 1). Even when outlier 25(OH)D
values in controls were excluded from analyses, mean
25(OH)D levels for SCD patients were still significantly
(p < 0.05) lower than those of their corresponding popula-
tion controls. Compared across the two geographical re-
gions, the Jamaican SCD cohort was not significantlyTable 1 Descriptive characteristics of study subjects†
Jamaica
Sickle cell cases
Latitude of country of study subjects 18° 15' North 1
Longitude of country of study subjects 77° 30' West
Sample size 20
Number of females (males) 12 (8)
Age (years) 23.7 ± 2.8b
Weight (kg) 54.0 ± 7.8c
Height (cm) 166.0 ± 7.4df
Body mass index (kg/m2) 19.5 ± 2.5g
Vitamin D (nmol/l) 45.4 ± 16.7h
†Values are expressed as means ± standard deviations; Values with one or two same
vitamin D comparison was adjusted for sex, age and body mass index; All controls we
2011–2012 (West Africa).different from the West African SCD cohort in mean age,
weight, BMI or levels of plasma 25(OH)D. Similar pattern
was observed when the population controls were com-
pared across the two regions (Table 1). For the purpose of
comparison, representative data on vitamin D in SCD pa-
tients from North American studies [4,22] are presented
in Table 2.
We also investigated possible correlations between
25(OH)D levels and laboratory measures of biomarkers
of renal or liver function (creatinine, urea, aspartate trans-
aminase and alanine transaminase) among the West
African SCD patients for whom these measures were
available. No relationship was observed between 25(OH)D
levels and the biomarkers (r < 0.2, p > 0.1).
Discussion
In this report we confirm that across a wide range of lat-
itudes patients with SCD have low circulating 25(OH)D
relative to control populations in the same geographic
region. As noted, stored samples separated by an average
of 10 years in Jamaica were analyzed and found to be
very stable. We can assume, therefore, that these cross-
sectional data are representative of a chronic state. In a
previous study of samples of 200 healthy Nigerian
women that were age-matched to samples of 200 healthy
African American women from metropolitan Chicago,
we observed that only a small proportion of 25(OH)D
distributions in the 2 populations overlapped [23], thus
demonstrating the sizeable effect of latitude. Also, the
difference in mean levels between these two populations
of shared ancestry (African Americans vs. Nigerians) is
essentially the same as what is observed between SCD
cases and controls in the same geographic location. Rep-
resentative data from North American studies [4,22]
(Table 2) demonstrate low 25(OH)D among SCD pa-
tients just as observed in the current study. Given theWest Africa
Controls Sickle cell cases Controls
8° 15' North Nigeria: 10° 00' North Ghana: 8° 00' North
77° 30' West Nigeria: 8° 00' East Ghana: 2° 00' West
459 50 497
243 (216) 26 (24) 290 (207)
34.3 ± 6.0a 23.3 ± 4.4b 34.3 ± 6.7a
75.9 ± 16.8 52.4 ± 9.7c 63.5 ± 11.5
169.3 ± 9.2d 164.1 ± 8.8ef 162.6 ± 8.2ef
26.7 ± 6.4 19.4 ± 3.0g 24.1 ± 4.5
72.2 ± 17.8 46.5 ± 12.8h 75.9 ± 17.2
superscript letters from ‘a’ to ‘h’ are pairwise non-significantly different (P < 0.05);
re sampled from 2010–2011 and sickle cell cases from 2000–2010 (Jamaica) and
Figure 1 Box plot of 25(OH)D levels in sickle cell disease cases and controls from Jamaica (Jam) and West Africa (WAf).
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among healthy Nigerians are at the same levels as found
among light-skinned European and North American pop-
ulations [23], we suggest that neither inherent inability to
synthesize active 25(OH)D nor limited sun exposure as a
result of reduced time spent outdoors can explain the US
findings. The great preponderance of 25(OH)D is pro-
duced through exposure to UVB radiation so it is also un-
likely that inadequate absorption of dietary vitamin D is
the key mechanism.
Investigators in Atlanta reported complete resolution
of chronic pain in a 16 year old female with SCD who
had severe osteoporosis with vitamin D supplementation
[2]; serum 25(OH)D levels were reported to be 20 nmol/l
[2] at baseline. Bone density improved slightly (+11%)
during the 20 months of follow up, and - surprisingly -
chronic headaches also resolved [2]. A small scale ran-
domized trial by the same investigators likewise showed a
significant improvement in the number of days with pain





Rovner et al. [4] Philadelphia, PA N:61 SCD-SS N:89 African-Ame
(latitude: 39.95°) Ages: 5-18 Ages: 6-18
Buison et al. [22] Philadelphia, PA N:61 SCD-SS N:33 African Ame
(latitude: 39.95°) Ages: 5-18 N:76 Non-African Am
Ages: 7-10
†25(OH)D Measurements: Rovner et al.: RIA kit (DiaSorin); Buison et al.: Radioiodinat
N, number; IQR, interquartile range.after a short course of high dose vitamin D therapy given
as oral cholecalciferol [7]. Thirty-nine patients were ran-
domized, however only 25 were available for end point
analysis [7]. Serum 25(OH)D rose significantly in the ini-
tial phases of the trial and lower numbers of pain days
were reported in the treatment group, although the im-
provement was not sustained [7]. The authors hypothesize
that lower 25(OH)D in SCD could be a result of a com-
bination of lower intake of vitamin D foods, reduced sun
exposure and increased utilization of vitamin D for bone
remodeling [7]. It seems unlikely, however, that the first
two proposed explanations accounted for the low levels of
vitamin D observed in the Jamaican and Nigerian sickle
cell cohorts, relative to the general population as intake of
foods high in vitamin D is universally low [24,25] and sun
exposure is extensive in these populations.
The potential health effects of low 25(OH)D have been
widely studied [26-30]. Despite claims from observa-
tional studies of a role in conditions varying from cancer
to obesity, the accumulated evidence was thought to berica
Vitamin D levels: 25(OH)D†
Cases Controls
rican 37 nmol/l (IQR: 25–82) 52 nmol/l (IQR: 37–90)
rican Total population: 25.5 ± 12.7 nmol/l African American:
60.7 ± 21.2 nmol/l
erican Ages: 7–10: N:25 29.5 ± 15.5 nmol/l Non-African American:
84.6 ± 23.5 nmol/l
ed tracer.
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recent Institute of Medicine report [1]. In a comprehen-
sive literature review, Aloia argues forcefully that there
is no evidence to support health-related consequences of
relatively low 25(OH)D beyond bone health [31]. The
strongest claim for an etiologic role for 25(OH)D has
been made in regard to multiple sclerosis (MS), where
month of conception – which in turn reflects circulating
25(OH)D in the mother – has been consistently shown
to be associated with this condition in adult offspring
[32]. Supplementation to prevent MS is however not
currently accepted practice.
Of additional interest in relation to 25(OH)D in SCD
patients in tropical countries would be the potential role
in mediating immune function [33]. It is interesting to
place the relative deficiency observed for patients with
SCD in the tropics in the context of global patterns of
25(OH)D [34,35]. As noted above, SCD patients in
Nigeria and Jamaica have similar levels of 25(OH)D to
those found among healthy African Americans [36]. As
Aloia has pointed out, there are likely to be compensa-
tory mechanisms within the metabolic pathway for 25
(OH)D, particularly in the kidney, that give the system
overall sufficient plasticity to maintain normal function
in the face of “low” circulating 25(OH)D levels [31].
Nonetheless, placing the findings among SCD patients
within this context does little to explain why circulating
25(OH)D should be lower than in controls, and nor does
it entirely resolve the question of whether there could be
pathologic consequences.
Conclusion
In conclusion, we have demonstrated that circulating
25(OH)D is lower in patients with SCD from equator-
ial regions to temperate latitudes. This finding, which ap-
pears to be characteristic of SCD, could offer a window on
vitamin D metabolism if the entirety of the metabolic path-
way could be described. In particular, we hypothesize that
metabolic demands on the liver in SCD may have reduced
the capacity to synthesize vitamin D binding protein.
Whether benefits would accrue from supplementation can
only be answered with sufficiently large randomized trials
where patients are randomized to vitamin D or placebo.
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